NDI Notification Draft Guidance In Brief

Outspoken NDI notification draft guidance opponent Jarrow Rogovin continues his criticism in comments that attorneys submitted for Jarrow Formulas. If adopted in its current form, the draft guidance would have “catastrophic effects” on the supplement industry, consumers and the economy, according to the comments attorneys Susan Brienza and Scott Polisky wrote. They estimate that each notification would cost a firm between $845,000 and $6.6 million and, because FDA likely would reject many notifications, $7.84 billion to $14.7 billion in supplement sales would be lost annually, they say. Brienza and Polisky also recommend that if FDA imposes the compliance standards stated in the draft guidance, the agency should withdraw the document and resubmit it as a proposed rule because the draft would establish regulatory requirements outside those created by DSHEA.

The comments also reflect common industry concerns about FDA’s thinking in the draft on chemical alteration, synthetics, amino acids, probiotics,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

ACIP ‘Pivot’ May Mean Variable US Coverage For New Vaccines, Higher Copays

 
• By 

Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By 

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

More from North America

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By 

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.